Male breast cancer: Results of the treatments and prognostic factors in 397 cases

Cutuli, B.; Lacroze, M.; Dilhuydy, Jean-Marie; Veiten, M.; Lafontan, B. De; Marchal, C.; Resbeut, M.; Graic, Y.; Campana, F.; Moncho-Bernier, V.; Gislain, C. De; Tortochaux, J.; Cuillere, J.C.; Reme-Saumon, M.; Nguyen, Tan Dat; Lesaunier, F.; Simple, T. Le; Gamelin, Érick; Héry, Michel; Berlié, J

doi:10.1016/0959-8049(95)00366-5

Cited by 201 publications

(193 citation statements)

References 26 publications

Supporting

Mentioning

154

Contrasting

Unclassified

Order By: Relevance

“…Male breast carcinoma (MBC) represents only 1% of all mammary cancers (Hecht and Winchester, 1994) and seems to behave more aggressively than female breast carcinomas (FBCs) (Ribeiro, 1985;Salvadori et al, 1994), although no difference in survival between MBC and FBC has been reported (Guinee et al, 1993;Cutuli et al, 1995;Weber-Chappuis et al, 1996). Treatment of MBC is far from standardization because of the uncommon nature of the disease, and no randomized comparisons of treatment have been carried out as in FBC.…”

mentioning

confidence: 99%

Androgen receptor expression in male breast carcinoma: lack of clinicopathological association

et al. 1999

View full text Add to dashboard Cite

Summary Androgen receptor (AR) expression was retrospectively analysed in 47 primary male breast carcinomas (MBCs) using a monoclonal antibody on formalin-fixed, paraffin-embedded tissues. AR immunopositivity was detected in 16 out of 47 (34%) cases. No association was found with patient age, tumour stage, progesterone receptor (PGR) or p53 protein expression. Well-differentiated MBCs tended to be AR positive more often than poorly differentiated ones (P = 0.08). A negative association was found between ARs and cell proliferative activity: MIB-1 scores were higher (25.4%) in AR-negative than in AR-positive cases (21.11%; P = 0.04). A strong positive association (P = 0.0001) was found between ARs and oestrogen receptors (ERs). In univariate analysis, ARs (as well as ERs and PGRs) were not correlated with overall survival; tumour histological grade (P = 0.02), size (P = 0.01), p53 expression (P = 0.0008) and MIB-1 scores (P = 0.0003) had strong prognostic value. In multivariate survival analysis, only p53 expression (P = 0.002) and histological grade (P = 0.02) retained independent prognostic significance. In conclusion, the lack of association between AR and most clinicopathological features and survival, together with the absence of prognostic value for ER/PGR status, suggest that MBCs are biologically different from female breast carcinomas and make it questionable to use antihormonal therapy for patients with MBC.

show abstract

mentioning

confidence: 99%

Androgen receptor expression in male breast carcinoma: lack of clinicopathological association

et al. 1999

View full text Add to dashboard Cite

show abstract

“…1-7 Some investigators report outcomes in men to be the same as in women, when patients are matched for histopathology, receptor state and disease stage. [3][4][5][6] Others suggest that men have poorer outcomes than women despite lower histologic grade, high ER content and small size. 6…”

Section: Discussionmentioning

confidence: 99%

“…These results are encouraging when compared to historic results of treatment with standard chemo-, radiation and hormonal therapy for patients with locally advanced disease. [1][2][3][4][5][6][7] However, evaluation of more cases and longer follow-up will be necessary to determine the incidence of late recurrence and possibility for cure in this population. The relative efficacy of standard and high-dose chemotherapy in men with breast cancer is probably not evaluable given the rarity of this disease.…”

Section: Discussionmentioning

confidence: 99%

“…1-7 While 64% of premenopausal and 75% of post-menopausal women have estrogen receptor (ER) positive cancers and 58% and 53%, respectively, have progesterone receptor (PR) positive tumors, according to a large study by Clark and colleagues, 8 80-90% of men have ER and PR positive breast cancer. [1][2][3][4][5][6][7] Recent advances in the molecular biology of breast cancer have allowed detection of differences in the BRCA1 and BRCA2 mutations in hereditary and spontaneously occurring female and male breast cancers (reviewed in Refs 9 and 10).…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3][4][5][6][7] Some investigators report outcomes in men to be the same as in women, when patients are matched for histopathology, receptor state and disease stage. [3][4][5][6] Others suggest that men have poorer outcomes than women despite lower histologic grade, high ER content and small size. 6 Increasing numbers of women now receive high-dose chemotherapy with autologous hematopoietic stem cell support (autotransplant) for both metastatic and high-risk stage 2/3 breast cancer.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Autotransplants in men with breast cancer

McCarthy

Hurd

Rowlings

et al. 1999

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:The purpose of this study was to determine the outcome of high-dose therapy with autologous hematopoietic stem cell support (autotransplants) in men with breast cancer. We studied 13 men receiving autotransplants for breast cancer and reported to the Autologous Blood and Marrow Transplant Registry (ABMTR) by 10 centers. Six men had stage 2 breast cancer, four had stage 3, and three had metastatic breast cancer. Of twelve tumors tested, all were estrogen receptor positive. Median age at transplant was 50 years. The most common conditioning regimen was cyclophosphamide, thiotepa and carboplatin (n = 5); the remaining eight men received other alkylator-based regimens. Three men received bone marrow, eight received blood stem cells, and two received both for hematopoietic support. All patients had hematopoietic recovery. There were no unexpected regimen-related toxicities. Of 10 men receiving autotransplants as adjuvant therapy, three relapsed 3, 5 and 50 months post-transplant and died 16, 19 and 67 months post-transplant. Seven of 10 are disease-free with median follow-up of 23 months (range 6-50 months). Of three men treated for metastatic breast cancer, one had progressive disease and two recurrent disease at 6, 7 and 16 months post-transplant. In conclusion, results of autotransplants for male breast cancer appear similar to those reported for women receiving autotransplants for breast cancer. Keywords: male breast cancer; autotransplant Male breast cancer accounts for fewer than 1% of all breast cancers. The annual incidence is Ͻ1 per 100 000 males. 1,2 Stage at diagnosis is generally more advanced than in women, possibly as a result of delays in diagnosis. Anatomic factors may also contribute. 3 The median age of men with breast cancer is 5 to 10 years older than women with breast cancer. 1-7 While 64% of premenopausal and 75% of post-menopausal women have estrogen receptor (ER) positive cancers and 58% and 53%, respectively, have progesterone receptor (PR) positive tumors, according to a large study by Clark and colleagues, 8 80-90% of men have ER and PR positive breast cancer. [1][2][3][4][5][6][7] Recent advances in the molecular biology of breast cancer have allowed detection of differences in the BRCA1 and BRCA2 mutations in hereditary and spontaneously occurring female and male breast cancers (reviewed in Refs 9 and 10).The standard therapy of breast cancer in men is similar to treatment in women, including surgery, radiation, hormone therapy and chemotherapy. 1-7 Some investigators report outcomes in men to be the same as in women, when patients are matched for histopathology, receptor state and disease stage. [3][4][5][6] Others suggest that men have poorer outcomes than women despite lower histologic grade, high ER content and small size. 6

show abstract

Men With Breast Cancer Have Better Disease-Specific Survival Than Women

El‐Tamer

Komenaka²,

Troxel³

et al. 2004

Arch Surg

View full text Add to dashboard Cite

Hypothesis:Male breast cancer patients have better disease-specific survival than carefully matched female breast cancer patients.Design: Retrospective study.Setting: University hospital. Patients and Methods:Each man in the breast cancer database at Columbia-Presbyterian Medical Center (New York, NY) between the years 1980 and 1998 was matched with a woman. Matching was done based on age and date of diagnosis, stage, and primary histologic findings. Main Outcome Measures:The overall survivals and disease-specific survivals of the male breast cancer group and female breast cancer group were compared.Results: Fifty-three male patients were matched with an equal number of female breast cancer patients. The Kaplan-Meier curves demonstrated that there was no significant difference in overall survival. The 5-and 10-year survivals for women were 0.77 and 0.51, and for men 0.77 and 0.56. When the Kaplan-Meier curves for breast cancerspecific survival were compared, however, there was a significant difference in the 5-and 10-year survivals (P =.05, log-rank test). For women, the 5-and 10-year disease-specific survival was 0.81 and 0.7, respectively, while for men it was 0.9 and 0.9, respectively. In a Cox regression analysis for time to death from breast cancer, stage was the only predictor of death that approached significance (P=.06). Conclusions:While the overall survivals were equivalent, male breast cancer patients had significantly better disease-specific survivals compared with their female counterparts. Male patients were 4 times more likely to die of other causes than their breast cancer.

show abstract

Male breast cancer: Results of the treatments and prognostic factors in 397 cases

Cited by 201 publications

References 26 publications

Androgen receptor expression in male breast carcinoma: lack of clinicopathological association

Androgen receptor expression in male breast carcinoma: lack of clinicopathological association

Autotransplants in men with breast cancer

Men With Breast Cancer Have Better Disease-Specific Survival Than Women

Contact Info

Product

Resources

About